Prescription Medicines
OlodipineHCT tab.10/40/12.5mg
- Product Category
- Antihypertensive Agents
- Active Ingredients
- Amlodipine, olmesartan, hydrochlorothiazide
- Appearance
- A grayish-red, round, film-coated tablet.
- Reimbursement Code
- 648104220
01 / 02
1. Composition and Strength
1 tablet
- Active ingredients:
Amlodipine besylate (KP) ------------ 13.888mg (10mg as amlodipine)
Olmesartan Medoxomil (USP) ------------ 40mg
Hydrochlorothiazide (EP) — 12.5 mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow)
- Other additives: silicified microcrystalline cellulose, Opadry II pink (85F25437), pregelatinized starch, croscarmellose sodium
2. Effectiveness
Essential hypertension in which blood pressure is not adequately controlled with combination therapy of amlodipine and olmesartan medoxomil
3. Dosage and dosage
Take this medication 1 tablet once a day with water, regardless of meal. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
Before administering this drug, it is recommended to adjust the dose of each ingredient (monotherapy or combination therapy of amlodipine and olmesartan medoxomil). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, you can consider switching to this drug right away as follows.
The maximum dosage of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure lowering effect occurs within 2 weeks after administration, the dose should be adjusted at intervals of 2 weeks or more, considering the patient's blood pressure response.
The recommended dosage is as follows.
- 5/20/12.5mg: Administered to patients whose blood pressure is not properly controlled with amlodipine/olmesartan medoxomil 5/20mg combination therapy.
- 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil 5/40mg combination therapy or 5/20/12.5mg of this drug.
- 5/40/25mg: 5/40/12.5mg of this drug is administered to patients whose blood pressure is not properly controlled.
- 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil 10/40mg combination therapy or 5/40/12.5mg of this drug.
- 10/40/25mg: Administer 5/40/25mg of this drug or 10/40/12.5mg of this drug to patients whose blood pressure is not properly controlled.
※ Refer to the following dosage increase steps.
(The contents of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide)
- Refer to the manual -
patients with renal impairment
The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60 mL/min) is 20/5/12.5 mg once daily. For patients with moderate renal failure, monitoring of potassium and creatinine levels is recommended.
This drug should not be administered to patients with severe renal impairment (creatinine clearance <30 mL/min).
Hepatic impairment patients
Caution should be exercised when administering to patients with mild or moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 mg once daily. In patients with hepatic impairment, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment.
Elderly (age 65 or older)
In general, administration is started at a low dose, and when adjusting the dose, the patient's renal or cardiac function, existing diseases, etc. must be taken into consideration. Older people may need to monitor their blood pressure more closely and more frequently. In particular, in elderly people over 75 years of age, there is very little experience with using this drug, so very careful monitoring is required when administering this drug.
pediatric
Safety and efficacy in pediatric patients under 18 years of age have not been established, so administration of this drug is not recommended.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, it can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant women)
2. Do not administer to the following patients
1) Patients with or history of hypersensitivity to this drug or its components, dihydropyridine derivatives, thiazide diuretics, or sulfonamide drugs
2) Pregnant or lactating women
3) Patients with severe hypotension
4) Patients with severe aortic stenosis
5) Hemodynamically unstable heart failure patients after acute myocardial infarction
6) Patients with acute or severe renal impairment (creatinine clearance <30mL/min), renal dialysis patients, anuric patients
7) Patients with severe hepatic impairment
8) Patients with biliary obstruction, biliary cirrhosis, and bile secretion arrest
9) Patients being treated for hyponatremia, hypokalemia, hypercalcemia, and symptomatic hyperuricemia (patients with gout or uric acid and its history)
10) Patients with Addison's disease
11) Shock patients (including cardiogenic shock)
12) Patients with diabetes and/or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2) taking aliskiren preparations (see section 5. Drug interactions)
3. Administer with caution to the following patients:
1) Patients with reduced blood volume or salt: In patients with an activated renin-angiotensin system, such as patients with reduced blood volume or salt (e.g., when receiving high doses of diuretics), symptoms of hypotension may appear in the early stages of administration of this drug, so appropriate measures must be taken before administering this drug. These patients should begin treatment while carefully observing their condition. If low blood pressure occurs, lay the patient down immediately and inject physiological saline intravenously if necessary. Even if a hypotensive reaction occurs temporarily, it does not indicate a contraindication to further treatment, and treatment can generally be continued without any difficulty once blood pressure is stabilized.
2) Inhibition of renin-angiotensin-aldosterone: Since olmesartan medoxomil inhibits the renin-angiotensin-aldosterone system, changes in kidney function may occur in sensitive patients receiving this drug. In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors or angiotensin receptor inhibitors may result in oliguria, progressive azotemia, (rarely) acute renal failure, or death. Similar results may occur when administering this drug.
3) Renal impairment patients and renal transplant patients: When this drug is administered to patients with renal dysfunction, it is necessary to periodically monitor serum potassium, creatinine, and uric acid levels. The use of this drug is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min), and its administration to patients who have undergone kidney transplantation has not been studied.
4) Patients with renovascular hypertension: In studies in which ACE inhibitors or angiotensin II receptor antagonists were administered to patients with unilateral or bilateral renal artery stenosis, the risk of severe hypotension and renal dysfunction increased. Although this drug has not been administered long-term to patients with unilateral or bilateral renal artery stenosis, similar results are expected.
5) Patients with hepatic impairment, liver disease, and advanced cirrhosis (hepatic coma may occur): Exposure to amlodipine and olmesartan medoxomil increased in patients with hepatic impairment. Additionally, thiazide diuretics must be used with caution when used in patients with impaired liver function or advanced liver disease, as even slight alterations in blood volume and electrolytes may trigger hepatic coma. For patients with moderate hepatic impairment, the dose of olmesartan medoxomil should not exceed 20 mg. This drug has little experience in using it in patients with mild and moderate hepatic impairment, and there is no experience in using it in patients with severe hepatic impairment, so its use is not recommended.
6) Patients with aortic and mitral stenosis, occlusive/hypertrophic myocardial disease: As with other vasodilators, special caution is required for patients with aortic or mitral stenosis or occlusive/hypertrophic cardiomyopathy.
7) Patients with primary aldosteronism: In general, patients with primary aldosteronism are not responsive to antihypertensive drugs that inhibit the renin-angiotensin system, so administration of this drug is not recommended for these patients.
8) Systemic lupus erythematosus patients: Thiazide diuretics are known to worsen or activate systemic lupus erythematosus.
9) Hypersensitivity reaction: Hypersensitivity reaction to hydrochlorothiazide can occur regardless of previous history of allergies or bronchial asthma, but hypersensitivity reaction is more likely to occur if there is such a history.
10) Patients taking diuretics continuously
11) Patients receiving digitalis, glucocorticosteroids, or adrenocorticotropic hormones
12) Patients with severe coronary arteriosclerosis or cerebral arteriosclerosis (if rapid diuresis occurs, blood concentration may occur due to rapid decrease in plasma volume, resulting in thromboembolism.)
13) Patients with hyperparathyroidism
14) Patients receiving salt restriction therapy
15) Patients after sympathectomy (the blood pressure lowering effect of this drug may increase)
16) Patients with diarrhea and vomiting
17) Elderly people
18) Patients who have gout or diabetes in themselves or their parents or siblings
19) Acute angle-closure glaucoma: Hydrochlorothiazide and sulfonamide cause acute transient myopia and acute angle-closure glaucoma. Deterioration of vision or eye pain has an acute onset and typically occurs within hours to weeks after starting treatment. A history of sulfonamide or penicillin allergy may be a risk factor for developing acute angle-closure glaucoma. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to stop hydrochlorothiazide as soon as possible. If intraocular pressure is not controlled, immediate medical or surgical treatment needs to be considered.
20) Heart failure: This drug may cause changes in kidney function due to inhibition of the renin-angiotensin-aldosterone system. In patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system, coadministration of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with urinary frequency and/or progressive azotemia and (rarely) acute renal failure and/or death. In the long-term, placebo-controlled trial of amlodipine in patients with NYHA class III or IV heart failure without ischemic etiology (PRAISE-2), amlodipine was associated with an increase in reports of pulmonary edema, despite no significant difference compared with placebo in the rate of worsening heart failure.
21) Pregnancy: Angiotensin II receptor antagonist administration should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated.
22) Photosensitivity: Cases of photosensitivity reactions to thiazide diuretics have been reported. If a photosensitivity reaction occurs while taking this drug, it is recommended to discontinue treatment. If re-administration of diuretics is necessary, it is recommended to protect areas exposed to light or artificial UVA.
23) Others: As with other antihypertensive drugs, excessive reduction in blood pressure may cause myocardial infarction or stroke in patients with ischemic heart disease or ischemic cerebrovascular disease. Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergies or bronchial asthma, but are more likely to occur in patients with such a history. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics. As with other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan was somewhat less effective in black patients than in other races. However, this effect was not observed in clinical trials of this drug that included black patients.
24) Non-melanoma skin cancer (NMSC)
Two epidemiological studies based on the Danish National Cancer Registry reported an increased risk of non-melanoma skin cancer, including basal cell and squamous cell carcinoma, with increasing cumulative exposure to hydrochlorothiazide. The photosensitizing effects of hydrochlorothiazide may contribute to the development of non-melanoma skin cancer.
Inform patients taking hydrochlorothiazide about the risk of non-melanoma skin cancer. Advise them to check their skin regularly for new lesions and report any suspicious skin lesions. Recommend preventive measures to minimize the risk, including limiting exposure to sunlight and ultraviolet radiation and using appropriate protection when exposed. Suspicious skin lesions should be examined promptly, including by biopsy where appropriate. Reconsider the use of hydrochlorothiazide in patients with a history of non-melanoma skin cancer.
4. Adverse reactions
1) The safety of this drug was evaluated in clinical trials involving 7,826 patients.
The most commonly reported adverse reactions during treatment with this drug are peripheral edema, headache, and dizziness.
Adverse events collected from clinical trials, post-marketing adverse event investigations, and spontaneous reports are listed in Table 1.
Frequency of occurrence is classified as follows; Very common (≥ 10%); Common (≥ 1%, <10%); Uncommon (≥ 0.1%, <1%); Rare (≥ 0.01%, <0.1%); Very rare (< 0.01%), unknown frequency (impossible to estimate from available data)
Table 1: Adverse reactions that occurred when administering this drug and its components - Refer to the instructions -
One case of rhabdomyolysis was reported in temporal relation to the administration of angiotensin II receptor blockers.
Chronic malabsorption (sprue)-like intestinal disease was reported in overseas post-marketing surveillance results of olmesartan medoxomil (see section 6. General precautions).
clinical trial
Data from one controlled clinical trial and epidemiological study suggested that high doses of olmesartan may increase cardiovascular risk in patients with diabetes, but this was not conclusive. The randomized, placebo-controlled, double-blind ROADMAP (Randomized Olmesartan And Diabetes Microalbuminuria Prevention) study administered 40 mg of olmesartan medoxomil per day or placebo to 4,447 patients with type 2 diabetes, normoalbuminuria, and at least one additional cardiovascular risk factor.
In this clinical trial, olmesartan medoxomil met the main endpoint by delaying the onset of microalbuminuria, but was not effective in reducing glomerular filtration rate (GFR).
Deaths due to cardiovascular disease (sudden cardiac death, fatal myocardial infarction, fatal stroke, reperfusion death) increased in the olmesartan medoxomil group compared to the placebo group (15 in the olmesartan medoxomil group, 3 in the placebo group, HR=4.9, 95% Cl 1.4-17.0). However, the risk of non-fatal myocardial infarction was low in the olmesartan medoxomil group (HR=0.64, 95% Cl 0.35-1.18).
Adverse reactions reported in clinical trials or post-marketing surveillance of the combination of amlodipine and olmesartan medoxomil that were not already reported in this drug, amlodipine monotherapy, or olmesartan medoxomil monotherapy, or that were reported at a higher frequency in the combination are listed in Table 2:
Table 2: Combination therapy of olmesartan medoxomil and amlodipine - see leaflet -
Adverse reactions reported in clinical trials or post-marketing surveillance of the combination of olmesartan medoxomil and hydrochlorothiazide that were not already reported in this drug, olmesartan medoxomil monotherapy, or hydrochlorothiazide monotherapy, or that were reported at a higher frequency in the combination are listed in Table 3:
Table 3: Combination therapy of olmesartan medoxomil and hydrochlorothiazide - see leaflet -
2) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 661 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 4.54% (30/661 people, 34 cases) regardless of causal relationship. Among these, serious adverse events unrelated to causal relationships are listed in the table below according to frequency of occurrence, and no serious adverse drug reactions for which causal relationships cannot be ruled out were reported. - Refer to table manual -
In addition, unexpected adverse events unrelated to causal relationships are listed in the following table according to frequency of occurrence, and no unexpected adverse drug reactions for which causal relationships cannot be ruled out were reported. - Refer to table manual -
3) Acute respiratory distress syndrome (ARDS) may occur in very rare cases related to hydrochlorothiazide.
5. Interaction
1) Drug interactions related to amlodipine/olmesartan medoxomil/hydrochlorothiazide
(1) Concurrent use is not recommended
① Lithium: There have been reports of a reversible increase in serum lithium concentration and toxicity during concurrent administration of lithium with angiotensin-converting enzyme inhibitors or, rarely, angiotensin II receptor antagonists. Additionally, thiazides may reduce renal clearance of lithium and, consequently, increase the risk of lithium toxicity. Therefore, co-administration of this drug and lithium is not recommended.
(2) Caution is required when using together
① Baclofen: It may have a strong antihypertensive effect.
② Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs (i.e., including acetylsalicylic acid (> 3 g/day), COX-2 inhibitors, and non-selective NSAIDs) can reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists. In some patients with renal insufficiency (e.g., dehydrated patients or elderly patients with renal insufficiency), coadministration of angiotensin II receptor antagonists and components that inhibit cyclooxygenase may result in a further deterioration of renal function, including the possibility of acute renal failure (usually reversible). Therefore, this combination treatment should be administered with caution, especially in the elderly. After starting combination treatment, patients should be adequately hydrated and renal function should be monitored regularly.
(3) Concomitant administration with caution
① Amifostine: Antihypertensive effect may increase.
② Other antihypertensive drugs: The blood pressure lowering effect of this drug may be increased by concomitant use of other antihypertensive drugs.
③ Alcohol, barbiturates, narcotics, or antidepressants: Orthostatic hypotension may occur.
2) Information on individual ingredients is as follows.
○ Amlodipine (refer to single drug approval)
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased exposure to simvastatin by approximately 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.
② Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. In this trial, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, when amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability, so concurrent use is not recommended.
③ Cytochrome P3A4 inhibitor: In elderly (69 to 87 years old) hypertensive patients, coadministration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18 to 43 years of age), coadministration of erythromycin did not significantly alter systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong cytochrome P3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be ruled out. Amlodipine should be administered with caution when administered in combination with cytochrome P3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
④ CYP3A4 inducer: Co-administration with CYP3A4 inducer (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
○ Olmesartan medoxomil (refer to single drug approval information)
① Potassium supplements and potassium-sparing diuretics: When looking at the administration of other drugs that act on the renin-angiotensin system, serum potassium levels may increase when this drug is co-administered with potassium-sparing diuretics, potassium supplements, preparations containing potassium salts, or preparations that can increase serum potassium levels (heparin).
② The blood pressure lowering effect of this drug may be increased when administered in combination with other antihypertensive drugs.
③ Lithium: There are reports that when ACE inhibitors and lithium are administered together, serum lithium levels rise reversibly and toxicity occurs. Since this phenomenon has been reported very rarely with this drug, co-administration of this drug and lithium is not recommended.
④ Non-steroidal anti-inflammatory drugs: When used together with other angiotensin II inhibitors and non-steroidal anti-inflammatory drugs (e.g., more than 3 grams of aspirin per day, COX-2 inhibitors), the decrease in glomerular filtration rate may increase. This risk is increased in patients with acute renal failure. Therefore, it is recommended to monitor renal function while replenishing fluids when starting treatment. Also, like other angiotensin II inhibitors, the antihypertensive effect of this drug may be weakened by nonsteroidal anti-inflammatory drugs.
⑤ Dual blockade of the renin-angiotensin system Dual blockade of the renin-angiotensin system by co-administration of angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), or aliskiren is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Therefore, for patients taking this drug in combination with other drugs that act on the angiotensin system, the patient's condition, such as blood pressure, renal function, and electrolyte concentration, should be closely monitored. Do not administer this drug and aliskiren together to patients with diabetes and/or renal impairment (glomerular filtration rate <60mL/min/1.73m2).
○ Hydrochlorothiazide (refer to single drug approval)
① There have been reports that co-administration of other diuretics (furosemide) and terfenadine caused QT prolongation and ventricular arrhythmia, so do not administer this drug and terfenadine together. Additionally, co-administration of this drug and astemizole may cause QT prolongation and ventricular arrhythmia, so do not administer this drug together.
② This drug has been reported to reduce the reactivity of blood vessel walls to vasopressor amines such as norepinephrine and increase the paralyzing effect of tubocurarine and similar compounds. Therefore, if this drug is being administered to a patient before surgery, caution should be exercised, such as temporarily discontinuing the administration.
③ Thiazide diuretics enhance the antihypertensive effect of other antihypertensive drugs (e.g., guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE blockers, angiotensin receptor blockers (ARBs) and direct renin blockers (DRIs), other diuretics, anesthetics, and alcohol). Additionally, caution should be exercised when coadministered with ACE inhibitors as it may increase the blood pressure lowering effect.
④ The hypokalemic effect of diuretics may be increased by concurrent administration with potassium-excreting diuretics (e.g. furosemide), corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives, or antiarrhythmic drugs.
⑤ Hypokalemia or hypomagnesemia caused by thiazide diuretics more easily causes cardiac arrhythmia caused by digitalis.
⑥ As lithium excretion through the kidneys is reduced, cardiotoxicity and neurotoxicity due to lithium may increase, so carefully monitor and adjust the dose.
⑦ Concurrent administration with non-steroidal anti-inflammatory analgesics (e.g. salicylic acid derivatives, indomethacin) may weaken the diuretic action and antihypertensive effects of thiazide diuretics. If hypovolemia occurs as a complication, acute renal failure may occur.
⑧ Avoid co-administration with vincarmine, erythromycin IV, and sultopramide as severe hypokalemia and bradycardia may occur.
⑨ Thiazide diuretics can change glucose tolerance, so the dose of insulin or oral diabetes medication may need to be adjusted. Because there is a risk of lactic acidosis caused by metformin, do not administer metformin and this drug together if the blood creatinine level is more than 1.5 mg/dl for men and 1.2 mg/dl for women.
⑩ Co-administration of amantadine and thiazide diuretics (including hydrochlorothiazide) may increase the risk of adverse reactions caused by amantadine.
⑪ Hemolytic anemia has been reported when methyldopa and hydrochlorothiazide are used together.
⑫ Concurrent administration of thiazide diuretics and calcium salts may cause hypercalcemia by increasing calcium reabsorption in the renal tubules.
⑬ When thiazide diuretics are used together with vitamin D or calcium salts, serum calcium levels may increase.
6. General precautions
1) Effects on metabolism and endocrine system: Administration of thiazide diuretics can cause glucose intolerance, so diabetic patients need to adjust the dose of insulin or oral hypoglycemic agents. Latent diabetes may occur during thiazide diuretic treatment. Additionally, blood levels of cholesterol and triglycerides may increase during treatment with thiazide diuretics. However, it is reported that the 12.5 mg dose contained in this drug has no or very minimal effect. Some patients treated with thiazide diuretics may develop hyperuricemia or develop overt gout.
2) Electrolyte imbalance: Serum electrolyte levels should be tested regularly for patients receiving diuretics. Thiazide diuretics may cause fluid or electrolyte imbalance (hyponatremia, hypochloralkalemia, hypokalemia). Gastrointestinal disorders such as dry mouth, thirst, weakness, drowsiness, anxiety, muscle pain or cramps, muscle fatigue, low blood pressure, decreased urine output, tachycardia, and nausea/vomiting are warning signs of fluid or electrolyte imbalance.
- Hyperkalemia: Like drugs that affect the renin-angiotensin system, hyperkalemia may occur when taking this drug, especially in patients with heart failure or renal failure. When administering this drug to patients with risk factors, it is necessary to sufficiently monitor serum potassium levels. Potassium-retaining diuretics, potassium supplements, or potassium-containing salts should be administered together with this drug with caution.
- Hypokalemia: Hypokalemia may occur when using thiazide diuretics, but hypokalemia caused by diuretics can be reduced by co-administration with olmesartan medoxomil. Patients with liver cirrhosis or patients receiving strong diuretics. Patients with inadequate electrolyte intake. Patients receiving concomitant corticosteroids or ACTH are at higher risk of developing hypokalemia.
- Hypercalcemia: Thiazide diuretics can reduce urinary calcium secretion and can temporarily and slightly increase serum calcium levels even in the absence of abnormal calcium metabolism. Hypercalcemia can be evidence of potential hyperparathyroidism, so stop taking thiazides before performing a parathyroid function test.
- Hypomagnesemia: Thiazide diuretics may cause hypomagnesemia by increasing urinary magnesium excretion.
3) Since the diuretic effect of this drug can occur rapidly, pay special attention to electrolyte imbalance and dehydration, and start administration at a low dose and increase the dose slowly.
4) In case of continuous use, electrolyte imbalance may occur, so inspect regularly.
5) Because the blood pressure lowering effect may cause dizziness, be careful not to operate machinery that involves risk, such as working at heights or driving a car.
6) Chronic malabsorption (Sprue)-like intestinal disease: After overseas marketing, a case of severe chronic diarrhea accompanied by significant weight loss was reported in a patient who had taken this drug for several months to several years. Villus retraction was commonly observed in the patient's intestinal biopsy. If a patient develops these symptoms during treatment and no other cause is identified, discontinuation of this drug should be considered. If symptoms disappear and chronic malabsorption-like intestinal disease is confirmed on biopsy, this medicine should not be taken again.
7) Acute respiratory toxicity
Very rare cases of severe acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary edema typically develops within minutes to hours after administration. Symptoms at onset include dyspnea, fever, pulmonary deterioration and hypotension. If ARDS is suspected, discontinue this medicine and provide appropriate treatment.
Hydrochlorothiazide should not be administered to patients who have experienced ARDS after previously taking hydrochlorothiazide.
7. Administration to pregnant women
1) Amlodipine/Olmesartan Medoxomil/Hydrochlorothiazide
The use of this drug during the second and third trimesters of pregnancy is contraindicated. Considering the effect of the individual components of this combination medication on pregnancy, its use in the first trimester of pregnancy is not recommended.
2) Information on individual ingredients is as follows.
○ Amlodipine
There have been no adequate and well-controlled clinical trials in pregnant women. During pregnancy, amlodipine should be used only when the potential benefits outweigh the potential risks to the fetus.
○ Olmesartan medoxomil
Administration of drugs that directly act on the renin-angiotensin system to a pregnant woman may cause damage or death to the fetus or newborn, and dozens of such cases have been reported worldwide in patients taking angiotensin converting enzyme (ACE) inhibitors. Therefore, if you find out that you are pregnant, you should stop taking this medicine as soon as possible. Taking drugs that act directly on the renin-angiotensin system during the second or third trimester of pregnancy may cause fetal and neonatal damage, including hypotension, neonatal skull development, anuria, reversible or irreversible renal failure, and death. In addition, oligohydramnios, which is known to occur due to decreased renal function in the fetus, has been reported. Oligohydramnios is associated with limb spasms, craniofacial deformities, and lung hypoplasia. In addition, although the relationship with the drug is not clear, premature birth, intrauterine growth retardation, and open ductus arteriosus have also been reported. These adverse reactions are unlikely to be caused by in utero drug exposure, which is limited to the first trimester of pregnancy. If the embryo or fetus is exposed to angiotensin II receptor antagonists only during the first trimester, the pregnant woman must be informed of the above information. However, if the patient becomes pregnant, she should stop taking this medication as soon as possible. In rare cases, there is no drug of choice other than an angiotensin II receptor antagonist (generally occurs in less than one in 1,000 pregnant women). At this time, the pregnant woman must be informed of the potential risk to the fetus, and the amniotic fluid environment must be evaluated through continuous ultrasound examination. If oligohydramnios appears, taking this medicine should be discontinued except in cases where it is necessary to save the life of the pregnant woman. Depending on the gestational age, tests such as Contraction Stress Testing, Nonstress Testing, or Biophysical Profiling can be performed appropriately. However, oligohydramnios may not appear even after an irreversible disorder has already occurred in the fetus. Infants who have been exposed to angiotensin II receptor antagonists in utero should be closely observed for hypotension, decreased urine output, and hyperkalemia. If there is a decrease in urine volume, attention should be paid to maintaining blood pressure and renal perfusion fluid. Exchange transfusion or dialysis may be performed to restore low blood pressure and replace decreased renal function. There is no clinical experience administering olmesartan medoxomil to pregnant women. No teratogenic effects were observed when the drug was administered orally to pregnant rats at doses up to 1000 mg/kg/day (240 times the maximum recommended human dose (MRHD) on a milligram per square meter basis) and when administered to pregnant rabbits up to 1 mg/kg/day (half the maximum recommended human dose; higher doses are lethal in rabbits, so the effects on fetal development could not be assessed). However, in rats, when administered at a dose of 1.6 mg/kg/day or more, the birth weight and weight gain of the pups were significantly reduced, the time to reach developmental milestones was delayed (delays in auricular differentiation, eruption of lower incisors, abdominal hair growth, testicular descent, eyelid differentiation, etc.), and when administered at a dose of 8 mg/kg/day or more, the occurrence of renal pelvic relaxation increased in a dose-dependent manner. The dose at which no effect on developmental toxicity is observed in rats is 0.3 mg/kg/day, which is approximately 1/10 of the maximum recommended human dose of 40 mg/day.
○ Hydrochlorothiazide
Thiazide diuretics can cause hyperbilirubinemia and thrombocytopenia in newborns or infants. In addition, because the diuretic effect may result in decreased plasma volume, blood concentration, and uterine and placental blood flow, it is administered only when the therapeutic benefits are judged to outweigh the risks in late pregnancy.
8. Administration to nursing mothers
1) Amlodipine/Olmesartan Medoxomil/Hydrochlorothiazide
There is no information on the use of this medication during breastfeeding, so its use is not recommended.
2) Information on individual ingredients is as follows.
○ Amlodipine
Limited data in lactating mothers suggest that amlodipine passes into human breast milk. Because there is a possibility that adverse reactions may occur in infants, nursing mothers should stop breastfeeding or administer this drug, considering the importance of this drug. Drugs from the dihydropyridine class, which are similar calcium channel blockers, are excreted in breast milk.
○ Olmesartan medoxomil
In the case of olmesartan medoxomil, it is not known whether it passes into breast milk in humans, but in rats, it passes into low concentrations. Because there is a possibility that adverse reactions may occur in infants, breastfeeding mothers should stop breastfeeding or administer this drug, taking into account the importance of this drug.
○ Hydrochlorothiazide
Thiazide diuretics have been reported to inhibit breast milk production and transfer into breast milk. Since there is a possibility of adverse reactions in infants, avoid administering this drug while breastfeeding and discontinue breast-feeding if unavoidable.
9. Administration to children
Safety and efficacy have not been established for pediatric patients under the age of 18, so administration of this drug is not recommended.
10. Administration to elderly people
In clinical trials of this drug, no differences in safety and efficacy were observed between elderly patients aged 65 years or older and younger patients. However, it cannot be ruled out that a more sensitive reaction may occur in some elderly people.
When amlodipine was administered orally, the time to peak plasma concentration was similar in young and elderly patients. There was a tendency for amlodipine clearance to decrease in elderly patients, resulting in increased AUC and elimination half-life. The increase in AUC and elimination half-life in patients with congestive heart failure was expected given the age group of patients in this study.
In patients with hypertension, the AUC of olmesartan at steady state increased by approximately 35% in elderly patients (65 to 75 years old) compared to young patients, and increased by approximately 44% in patients aged 75 or older. This may be partly related to the average decrease in renal function in this patient group. In general, dose selection for the elderly should be cautious, usually starting at the lowest dose of the dosage range, and taking into account the frequent decline in liver, kidney, and heart function in the elderly, as well as concomitant diseases or concomitant medications.
Limited data suggest that systemic clearance of hydrochlorothiazide is reduced in elderly patients compared to younger patients.
11. Treatment in case of overdose
1) Symptoms: The maximum dose of this drug is 40mg/10mg/25mg once a day, and there are no research reports on overdose of this drug in humans. The most likely symptom of overdose of this drug is hypotension. The most frequent symptoms of olmesartan medoxomil overdose are low blood pressure and palpitations. When parasympathetic stimulation occurs, bradycardia may occur. Overdosage may cause excessive peripheral vasodilation with marked hypotension, which may result in tachycardia. In case of overdose of this drug, it is necessary to frequently monitor cardiac and respiratory function and frequently measure blood pressure. If hypotension occurs, cardiovascular support therapy, including raising blood pressure, and fluid administration should be administered. If hypotension does not respond to these therapies, attention should be paid to circulating fluid volume and urine output, and administration of vasopressors such as phenylephrine should be considered. Intravenous calcium gluconate may help reverse calcium channel blockage. Since amlodipine is highly bound to proteins, hemodialysis may not be helpful. The most common symptoms and signs that may appear in humans during hydrochlorothiazide overdose are electrolyte deficiency (hypokalemia, hypochloremia, hyponatremia) and dehydration caused by excessive diuresis. The most common signs and symptoms of overdose are nausea and lethargy. If digitalis is also administered, hypokalemia may worsen cardiac arrhythmias. Additionally, non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
2) Treatment: In case of overdose of this drug, observe the patient closely and take appropriate measures if symptoms appear. Inducing vomiting or gastric lavage may be one method, and using activated charcoal may also be useful. Serum electrolytes and creatinine should be monitored frequently, and if hypotension occurs, the patient should be placed supine and salt and fluid substitutes should be quickly administered. Clinically significant hypotension resulting from overdose of this drug requires active cardiovascular support therapy, including close monitoring of cardiac and pulmonary function and ensuring circulating fluid volume and urine output by maintaining extremities elevated above the body. Unless the use of vasoconstrictors is contraindicated, vasoconstrictors can help restore vascular tone and blood pressure. Intravenous administration of calcium gluconate may be beneficial in reversing the effects of calcium channel blockers. Since amlodipine is highly bound to proteins, hemodialysis may not be helpful. It is not known whether olmesartan or hydrochlorothiazide are removed by hemodialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Avoid humidity and heat, and store carefully to avoid direct exposure to light.
3) Be careful as changing it to another container may cause an accident or is undesirable in terms of maintaining quality.
13. Pharmaceutical equivalence test information
A. The test drug amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 10/40/12.5 mg (JW Pharmaceutical Co., Ltd.) and the reference drug Sevica HCT tablet 10/40/12.5 mg (Daiichi Sankyo Korea Co., Ltd.) were administered as a single tablet to 35 healthy adults in a 2×2 crossover study on an empty stomach. As a result of measuring amlodipine, olmesartan, and hydrochlorothiazide in the blood through oral administration, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
Table: Documentation Reference
B. According to Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 5/40/12.5 mg (JW Joongwae Pharmaceutical Co., Ltd.) is the reference drug. Comparative dissolution test data with amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 10/40/12.5 mg (JW Joongwae Pharmaceutical Co., Ltd.) were submitted, and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
※ This drug was manufactured using the same raw materials as Amlodipine Besylate/Olmesartan Medoxomil/Hydrochlorothiazide Tablets 10/40/12.5 mg and 5/40/12.5 mg, and the entire process was manufactured by JW Jung-Woe Pharmaceutical Co., Ltd. using the same manufacturing method.
14. Others
1) This drug and other angiotensin antagonists showed slightly less blood pressure lowering effect in black people than in other races. This is believed to be because, among black hypertensive patients, the frequency of patients with low renin levels is generally higher.
2) For patients who need rest at night, it is advisable to administer it in the morning to avoid urination at night.
5. How to save
Airtight container, stored at room temperature (1-30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu × 3)
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredients:
Amlodipine besylate (KP) ------------ 13.888mg (10mg as amlodipine)
Olmesartan Medoxomil (USP) ------------ 40mg
Hydrochlorothiazide (EP) — 12.5 mg
- Additives (animal-derived ingredients): Magnesium stearate (beef, beef tallow)
- Other additives: silicified microcrystalline cellulose, Opadry II pink (85F25437), pregelatinized starch, croscarmellose sodium
2. Effectiveness
Essential hypertension in which blood pressure is not adequately controlled with combination therapy of amlodipine and olmesartan medoxomil
3. Dosage and dosage
Take this medication 1 tablet once a day with water, regardless of meal. If possible, it is recommended to take it at the same time every day (e.g. in the morning).
Before administering this drug, it is recommended to adjust the dose of each ingredient (monotherapy or combination therapy of amlodipine and olmesartan medoxomil). However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, you can consider switching to this drug right away as follows.
The maximum dosage of this drug is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Since the maximum blood pressure lowering effect occurs within 2 weeks after administration, the dose should be adjusted at intervals of 2 weeks or more, considering the patient's blood pressure response.
The recommended dosage is as follows.
- 5/20/12.5mg: Administered to patients whose blood pressure is not properly controlled with amlodipine/olmesartan medoxomil 5/20mg combination therapy.
- 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil 5/40mg combination therapy or 5/20/12.5mg of this drug.
- 5/40/25mg: 5/40/12.5mg of this drug is administered to patients whose blood pressure is not properly controlled.
- 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine/olmesartan medoxomil 10/40mg combination therapy or 5/40/12.5mg of this drug.
- 10/40/25mg: Administer 5/40/25mg of this drug or 10/40/12.5mg of this drug to patients whose blood pressure is not properly controlled.
※ Refer to the following dosage increase steps.
(The contents of each ingredient are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide)
- Refer to the manual -
patients with renal impairment
The maximum dose of this drug for patients with mild to moderate renal impairment (creatinine clearance 30-60 mL/min) is 20/5/12.5 mg once daily. For patients with moderate renal failure, monitoring of potassium and creatinine levels is recommended.
This drug should not be administered to patients with severe renal impairment (creatinine clearance <30 mL/min).
Hepatic impairment patients
Caution should be exercised when administering to patients with mild or moderate hepatic impairment. The maximum dose of this drug for patients with moderate hepatic impairment is 5/20/12.5 mg once daily. In patients with hepatic impairment, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment.
Elderly (age 65 or older)
In general, administration is started at a low dose, and when adjusting the dose, the patient's renal or cardiac function, existing diseases, etc. must be taken into consideration. Older people may need to monitor their blood pressure more closely and more frequently. In particular, in elderly people over 75 years of age, there is very little experience with using this drug, so very careful monitoring is required when administering this drug.
pediatric
Safety and efficacy in pediatric patients under 18 years of age have not been established, so administration of this drug is not recommended.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, it can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to section 7. Administration to pregnant women)
2. Do not administer to the following patients
1) Patients with or history of hypersensitivity to this drug or its components, dihydropyridine derivatives, thiazide diuretics, or sulfonamide drugs
2) Pregnant or lactating women
3) Patients with severe hypotension
4) Patients with severe aortic stenosis
5) Hemodynamically unstable heart failure patients after acute myocardial infarction
6) Patients with acute or severe renal impairment (creatinine clearance <30mL/min), renal dialysis patients, anuric patients
7) Patients with severe hepatic impairment
8) Patients with biliary obstruction, biliary cirrhosis, and bile secretion arrest
9) Patients being treated for hyponatremia, hypokalemia, hypercalcemia, and symptomatic hyperuricemia (patients with gout or uric acid and its history)
10) Patients with Addison's disease
11) Shock patients (including cardiogenic shock)
12) Patients with diabetes and/or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2) taking aliskiren preparations (see section 5. Drug interactions)
3. Administer with caution to the following patients:
1) Patients with reduced blood volume or salt: In patients with an activated renin-angiotensin system, such as patients with reduced blood volume or salt (e.g., when receiving high doses of diuretics), symptoms of hypotension may appear in the early stages of administration of this drug, so appropriate measures must be taken before administering this drug. These patients should begin treatment while carefully observing their condition. If low blood pressure occurs, lay the patient down immediately and inject physiological saline intravenously if necessary. Even if a hypotensive reaction occurs temporarily, it does not indicate a contraindication to further treatment, and treatment can generally be continued without any difficulty once blood pressure is stabilized.
2) Inhibition of renin-angiotensin-aldosterone: Since olmesartan medoxomil inhibits the renin-angiotensin-aldosterone system, changes in kidney function may occur in sensitive patients receiving this drug. In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors or angiotensin receptor inhibitors may result in oliguria, progressive azotemia, (rarely) acute renal failure, or death. Similar results may occur when administering this drug.
3) Renal impairment patients and renal transplant patients: When this drug is administered to patients with renal dysfunction, it is necessary to periodically monitor serum potassium, creatinine, and uric acid levels. The use of this drug is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min), and its administration to patients who have undergone kidney transplantation has not been studied.
4) Patients with renovascular hypertension: In studies in which ACE inhibitors or angiotensin II receptor antagonists were administered to patients with unilateral or bilateral renal artery stenosis, the risk of severe hypotension and renal dysfunction increased. Although this drug has not been administered long-term to patients with unilateral or bilateral renal artery stenosis, similar results are expected.
5) Patients with hepatic impairment, liver disease, and advanced cirrhosis (hepatic coma may occur): Exposure to amlodipine and olmesartan medoxomil increased in patients with hepatic impairment. Additionally, thiazide diuretics must be used with caution when used in patients with impaired liver function or advanced liver disease, as even slight alterations in blood volume and electrolytes may trigger hepatic coma. For patients with moderate hepatic impairment, the dose of olmesartan medoxomil should not exceed 20 mg. This drug has little experience in using it in patients with mild and moderate hepatic impairment, and there is no experience in using it in patients with severe hepatic impairment, so its use is not recommended.
6) Patients with aortic and mitral stenosis, occlusive/hypertrophic myocardial disease: As with other vasodilators, special caution is required for patients with aortic or mitral stenosis or occlusive/hypertrophic cardiomyopathy.
7) Patients with primary aldosteronism: In general, patients with primary aldosteronism are not responsive to antihypertensive drugs that inhibit the renin-angiotensin system, so administration of this drug is not recommended for these patients.
8) Systemic lupus erythematosus patients: Thiazide diuretics are known to worsen or activate systemic lupus erythematosus.
9) Hypersensitivity reaction: Hypersensitivity reaction to hydrochlorothiazide can occur regardless of previous history of allergies or bronchial asthma, but hypersensitivity reaction is more likely to occur if there is such a history.
10) Patients taking diuretics continuously
11) Patients receiving digitalis, glucocorticosteroids, or adrenocorticotropic hormones
12) Patients with severe coronary arteriosclerosis or cerebral arteriosclerosis (if rapid diuresis occurs, blood concentration may occur due to rapid decrease in plasma volume, resulting in thromboembolism.)
13) Patients with hyperparathyroidism
14) Patients receiving salt restriction therapy
15) Patients after sympathectomy (the blood pressure lowering effect of this drug may increase)
16) Patients with diarrhea and vomiting
17) Elderly people
18) Patients who have gout or diabetes in themselves or their parents or siblings
19) Acute angle-closure glaucoma: Hydrochlorothiazide and sulfonamide cause acute transient myopia and acute angle-closure glaucoma. Deterioration of vision or eye pain has an acute onset and typically occurs within hours to weeks after starting treatment. A history of sulfonamide or penicillin allergy may be a risk factor for developing acute angle-closure glaucoma. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to stop hydrochlorothiazide as soon as possible. If intraocular pressure is not controlled, immediate medical or surgical treatment needs to be considered.
20) Heart failure: This drug may cause changes in kidney function due to inhibition of the renin-angiotensin-aldosterone system. In patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system, coadministration of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with urinary frequency and/or progressive azotemia and (rarely) acute renal failure and/or death. In the long-term, placebo-controlled trial of amlodipine in patients with NYHA class III or IV heart failure without ischemic etiology (PRAISE-2), amlodipine was associated with an increase in reports of pulmonary edema, despite no significant difference compared with placebo in the rate of worsening heart failure.
21) Pregnancy: Angiotensin II receptor antagonist administration should not be started during pregnancy. If continued treatment with angiotensin II receptor antagonists is not essential, patients planning pregnancy should substitute other antihypertensive agents with an established safety profile for use in pregnancy. If pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be discontinued as soon as possible and, if appropriate, treatment with another treatment should be initiated.
22) Photosensitivity: Cases of photosensitivity reactions to thiazide diuretics have been reported. If a photosensitivity reaction occurs while taking this drug, it is recommended to discontinue treatment. If re-administration of diuretics is necessary, it is recommended to protect areas exposed to light or artificial UVA.
23) Others: As with other antihypertensive drugs, excessive reduction in blood pressure may cause myocardial infarction or stroke in patients with ischemic heart disease or ischemic cerebrovascular disease. Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergies or bronchial asthma, but are more likely to occur in patients with such a history. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics. As with other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan was somewhat less effective in black patients than in other races. However, this effect was not observed in clinical trials of this drug that included black patients.
24) Non-melanoma skin cancer (NMSC)
Two epidemiological studies based on the Danish National Cancer Registry reported an increased risk of non-melanoma skin cancer, including basal cell and squamous cell carcinoma, with increasing cumulative exposure to hydrochlorothiazide. The photosensitizing effects of hydrochlorothiazide may contribute to the development of non-melanoma skin cancer.
Inform patients taking hydrochlorothiazide about the risk of non-melanoma skin cancer. Advise them to check their skin regularly for new lesions and report any suspicious skin lesions. Recommend preventive measures to minimize the risk, including limiting exposure to sunlight and ultraviolet radiation and using appropriate protection when exposed. Suspicious skin lesions should be examined promptly, including by biopsy where appropriate. Reconsider the use of hydrochlorothiazide in patients with a history of non-melanoma skin cancer.
4. Adverse reactions
1) The safety of this drug was evaluated in clinical trials involving 7,826 patients.
The most commonly reported adverse reactions during treatment with this drug are peripheral edema, headache, and dizziness.
Adverse events collected from clinical trials, post-marketing adverse event investigations, and spontaneous reports are listed in Table 1.
Frequency of occurrence is classified as follows; Very common (≥ 10%); Common (≥ 1%, <10%); Uncommon (≥ 0.1%, <1%); Rare (≥ 0.01%, <0.1%); Very rare (< 0.01%), unknown frequency (impossible to estimate from available data)
Table 1: Adverse reactions that occurred when administering this drug and its components - Refer to the instructions -
One case of rhabdomyolysis was reported in temporal relation to the administration of angiotensin II receptor blockers.
Chronic malabsorption (sprue)-like intestinal disease was reported in overseas post-marketing surveillance results of olmesartan medoxomil (see section 6. General precautions).
clinical trial
Data from one controlled clinical trial and epidemiological study suggested that high doses of olmesartan may increase cardiovascular risk in patients with diabetes, but this was not conclusive. The randomized, placebo-controlled, double-blind ROADMAP (Randomized Olmesartan And Diabetes Microalbuminuria Prevention) study administered 40 mg of olmesartan medoxomil per day or placebo to 4,447 patients with type 2 diabetes, normoalbuminuria, and at least one additional cardiovascular risk factor.
In this clinical trial, olmesartan medoxomil met the main endpoint by delaying the onset of microalbuminuria, but was not effective in reducing glomerular filtration rate (GFR).
Deaths due to cardiovascular disease (sudden cardiac death, fatal myocardial infarction, fatal stroke, reperfusion death) increased in the olmesartan medoxomil group compared to the placebo group (15 in the olmesartan medoxomil group, 3 in the placebo group, HR=4.9, 95% Cl 1.4-17.0). However, the risk of non-fatal myocardial infarction was low in the olmesartan medoxomil group (HR=0.64, 95% Cl 0.35-1.18).
Adverse reactions reported in clinical trials or post-marketing surveillance of the combination of amlodipine and olmesartan medoxomil that were not already reported in this drug, amlodipine monotherapy, or olmesartan medoxomil monotherapy, or that were reported at a higher frequency in the combination are listed in Table 2:
Table 2: Combination therapy of olmesartan medoxomil and amlodipine - see leaflet -
Adverse reactions reported in clinical trials or post-marketing surveillance of the combination of olmesartan medoxomil and hydrochlorothiazide that were not already reported in this drug, olmesartan medoxomil monotherapy, or hydrochlorothiazide monotherapy, or that were reported at a higher frequency in the combination are listed in Table 3:
Table 3: Combination therapy of olmesartan medoxomil and hydrochlorothiazide - see leaflet -
2) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 661 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 4.54% (30/661 people, 34 cases) regardless of causal relationship. Among these, serious adverse events unrelated to causal relationships are listed in the table below according to frequency of occurrence, and no serious adverse drug reactions for which causal relationships cannot be ruled out were reported. - Refer to table manual -
In addition, unexpected adverse events unrelated to causal relationships are listed in the following table according to frequency of occurrence, and no unexpected adverse drug reactions for which causal relationships cannot be ruled out were reported. - Refer to table manual -
3) Acute respiratory distress syndrome (ARDS) may occur in very rare cases related to hydrochlorothiazide.
5. Interaction
1) Drug interactions related to amlodipine/olmesartan medoxomil/hydrochlorothiazide
(1) Concurrent use is not recommended
① Lithium: There have been reports of a reversible increase in serum lithium concentration and toxicity during concurrent administration of lithium with angiotensin-converting enzyme inhibitors or, rarely, angiotensin II receptor antagonists. Additionally, thiazides may reduce renal clearance of lithium and, consequently, increase the risk of lithium toxicity. Therefore, co-administration of this drug and lithium is not recommended.
(2) Caution is required when using together
① Baclofen: It may have a strong antihypertensive effect.
② Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs (i.e., including acetylsalicylic acid (> 3 g/day), COX-2 inhibitors, and non-selective NSAIDs) can reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists. In some patients with renal insufficiency (e.g., dehydrated patients or elderly patients with renal insufficiency), coadministration of angiotensin II receptor antagonists and components that inhibit cyclooxygenase may result in a further deterioration of renal function, including the possibility of acute renal failure (usually reversible). Therefore, this combination treatment should be administered with caution, especially in the elderly. After starting combination treatment, patients should be adequately hydrated and renal function should be monitored regularly.
(3) Concomitant administration with caution
① Amifostine: Antihypertensive effect may increase.
② Other antihypertensive drugs: The blood pressure lowering effect of this drug may be increased by concomitant use of other antihypertensive drugs.
③ Alcohol, barbiturates, narcotics, or antidepressants: Orthostatic hypotension may occur.
2) Information on individual ingredients is as follows.
○ Amlodipine (refer to single drug approval)
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased exposure to simvastatin by approximately 77% compared to administration of simvastatin alone. In patients receiving amlodipine, the maximum daily dose of simvastatin is up to 20 mg.
② Grapefruit juice: A single co-administration of 240 mL of grapefruit juice and 10 mg of amlodipine in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine. In this trial, the impact of genetic polymorphisms in CYP3A4, the main metabolic pathway for amlodipine, was not evaluated. Therefore, when amlodipine is used in combination with grapefruit or grapefruit juice, the blood pressure lowering effect may increase in some patients due to increased bioavailability, so concurrent use is not recommended.
③ Cytochrome P3A4 inhibitor: In elderly (69 to 87 years old) hypertensive patients, coadministration of 180 mg of diltiazem and 5 mg of amlodipine per day increased the systemic exposure of amlodipine by 57%. In healthy volunteers (18 to 43 years of age), coadministration of erythromycin did not significantly alter systemic exposure to amlodipine (22% increase in AUC). Although the clinical relevance of this has not been revealed, pharmacokinetic changes may be more evident in elderly people. The possibility that strong cytochrome P3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase plasma concentrations of amlodipine to levels higher than those seen with co-administration with diltiazem cannot be ruled out. Amlodipine should be administered with caution when administered in combination with cytochrome P3A4 inhibitors. However, no adverse reactions resulting from this drug interaction have been reported.
④ CYP3A4 inducer: Co-administration with CYP3A4 inducer (e.g. rifampicin, St. John's wort (hypericum perforatum)) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
○ Olmesartan medoxomil (refer to single drug approval information)
① Potassium supplements and potassium-sparing diuretics: When looking at the administration of other drugs that act on the renin-angiotensin system, serum potassium levels may increase when this drug is co-administered with potassium-sparing diuretics, potassium supplements, preparations containing potassium salts, or preparations that can increase serum potassium levels (heparin).
② The blood pressure lowering effect of this drug may be increased when administered in combination with other antihypertensive drugs.
③ Lithium: There are reports that when ACE inhibitors and lithium are administered together, serum lithium levels rise reversibly and toxicity occurs. Since this phenomenon has been reported very rarely with this drug, co-administration of this drug and lithium is not recommended.
④ Non-steroidal anti-inflammatory drugs: When used together with other angiotensin II inhibitors and non-steroidal anti-inflammatory drugs (e.g., more than 3 grams of aspirin per day, COX-2 inhibitors), the decrease in glomerular filtration rate may increase. This risk is increased in patients with acute renal failure. Therefore, it is recommended to monitor renal function while replenishing fluids when starting treatment. Also, like other angiotensin II inhibitors, the antihypertensive effect of this drug may be weakened by nonsteroidal anti-inflammatory drugs.
⑤ Dual blockade of the renin-angiotensin system Dual blockade of the renin-angiotensin system by co-administration of angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), or aliskiren is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Therefore, for patients taking this drug in combination with other drugs that act on the angiotensin system, the patient's condition, such as blood pressure, renal function, and electrolyte concentration, should be closely monitored. Do not administer this drug and aliskiren together to patients with diabetes and/or renal impairment (glomerular filtration rate <60mL/min/1.73m2).
○ Hydrochlorothiazide (refer to single drug approval)
① There have been reports that co-administration of other diuretics (furosemide) and terfenadine caused QT prolongation and ventricular arrhythmia, so do not administer this drug and terfenadine together. Additionally, co-administration of this drug and astemizole may cause QT prolongation and ventricular arrhythmia, so do not administer this drug together.
② This drug has been reported to reduce the reactivity of blood vessel walls to vasopressor amines such as norepinephrine and increase the paralyzing effect of tubocurarine and similar compounds. Therefore, if this drug is being administered to a patient before surgery, caution should be exercised, such as temporarily discontinuing the administration.
③ Thiazide diuretics enhance the antihypertensive effect of other antihypertensive drugs (e.g., guanethidine, methyldopa, beta-blockers, vasodilators, calcium channel blockers, ACE blockers, angiotensin receptor blockers (ARBs) and direct renin blockers (DRIs), other diuretics, anesthetics, and alcohol). Additionally, caution should be exercised when coadministered with ACE inhibitors as it may increase the blood pressure lowering effect.
④ The hypokalemic effect of diuretics may be increased by concurrent administration with potassium-excreting diuretics (e.g. furosemide), corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G and salicylic acid derivatives, or antiarrhythmic drugs.
⑤ Hypokalemia or hypomagnesemia caused by thiazide diuretics more easily causes cardiac arrhythmia caused by digitalis.
⑥ As lithium excretion through the kidneys is reduced, cardiotoxicity and neurotoxicity due to lithium may increase, so carefully monitor and adjust the dose.
⑦ Concurrent administration with non-steroidal anti-inflammatory analgesics (e.g. salicylic acid derivatives, indomethacin) may weaken the diuretic action and antihypertensive effects of thiazide diuretics. If hypovolemia occurs as a complication, acute renal failure may occur.
⑧ Avoid co-administration with vincarmine, erythromycin IV, and sultopramide as severe hypokalemia and bradycardia may occur.
⑨ Thiazide diuretics can change glucose tolerance, so the dose of insulin or oral diabetes medication may need to be adjusted. Because there is a risk of lactic acidosis caused by metformin, do not administer metformin and this drug together if the blood creatinine level is more than 1.5 mg/dl for men and 1.2 mg/dl for women.
⑩ Co-administration of amantadine and thiazide diuretics (including hydrochlorothiazide) may increase the risk of adverse reactions caused by amantadine.
⑪ Hemolytic anemia has been reported when methyldopa and hydrochlorothiazide are used together.
⑫ Concurrent administration of thiazide diuretics and calcium salts may cause hypercalcemia by increasing calcium reabsorption in the renal tubules.
⑬ When thiazide diuretics are used together with vitamin D or calcium salts, serum calcium levels may increase.
6. General precautions
1) Effects on metabolism and endocrine system: Administration of thiazide diuretics can cause glucose intolerance, so diabetic patients need to adjust the dose of insulin or oral hypoglycemic agents. Latent diabetes may occur during thiazide diuretic treatment. Additionally, blood levels of cholesterol and triglycerides may increase during treatment with thiazide diuretics. However, it is reported that the 12.5 mg dose contained in this drug has no or very minimal effect. Some patients treated with thiazide diuretics may develop hyperuricemia or develop overt gout.
2) Electrolyte imbalance: Serum electrolyte levels should be tested regularly for patients receiving diuretics. Thiazide diuretics may cause fluid or electrolyte imbalance (hyponatremia, hypochloralkalemia, hypokalemia). Gastrointestinal disorders such as dry mouth, thirst, weakness, drowsiness, anxiety, muscle pain or cramps, muscle fatigue, low blood pressure, decreased urine output, tachycardia, and nausea/vomiting are warning signs of fluid or electrolyte imbalance.
- Hyperkalemia: Like drugs that affect the renin-angiotensin system, hyperkalemia may occur when taking this drug, especially in patients with heart failure or renal failure. When administering this drug to patients with risk factors, it is necessary to sufficiently monitor serum potassium levels. Potassium-retaining diuretics, potassium supplements, or potassium-containing salts should be administered together with this drug with caution.
- Hypokalemia: Hypokalemia may occur when using thiazide diuretics, but hypokalemia caused by diuretics can be reduced by co-administration with olmesartan medoxomil. Patients with liver cirrhosis or patients receiving strong diuretics. Patients with inadequate electrolyte intake. Patients receiving concomitant corticosteroids or ACTH are at higher risk of developing hypokalemia.
- Hypercalcemia: Thiazide diuretics can reduce urinary calcium secretion and can temporarily and slightly increase serum calcium levels even in the absence of abnormal calcium metabolism. Hypercalcemia can be evidence of potential hyperparathyroidism, so stop taking thiazides before performing a parathyroid function test.
- Hypomagnesemia: Thiazide diuretics may cause hypomagnesemia by increasing urinary magnesium excretion.
3) Since the diuretic effect of this drug can occur rapidly, pay special attention to electrolyte imbalance and dehydration, and start administration at a low dose and increase the dose slowly.
4) In case of continuous use, electrolyte imbalance may occur, so inspect regularly.
5) Because the blood pressure lowering effect may cause dizziness, be careful not to operate machinery that involves risk, such as working at heights or driving a car.
6) Chronic malabsorption (Sprue)-like intestinal disease: After overseas marketing, a case of severe chronic diarrhea accompanied by significant weight loss was reported in a patient who had taken this drug for several months to several years. Villus retraction was commonly observed in the patient's intestinal biopsy. If a patient develops these symptoms during treatment and no other cause is identified, discontinuation of this drug should be considered. If symptoms disappear and chronic malabsorption-like intestinal disease is confirmed on biopsy, this medicine should not be taken again.
7) Acute respiratory toxicity
Very rare cases of severe acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary edema typically develops within minutes to hours after administration. Symptoms at onset include dyspnea, fever, pulmonary deterioration and hypotension. If ARDS is suspected, discontinue this medicine and provide appropriate treatment.
Hydrochlorothiazide should not be administered to patients who have experienced ARDS after previously taking hydrochlorothiazide.
7. Administration to pregnant women
1) Amlodipine/Olmesartan Medoxomil/Hydrochlorothiazide
The use of this drug during the second and third trimesters of pregnancy is contraindicated. Considering the effect of the individual components of this combination medication on pregnancy, its use in the first trimester of pregnancy is not recommended.
2) Information on individual ingredients is as follows.
○ Amlodipine
There have been no adequate and well-controlled clinical trials in pregnant women. During pregnancy, amlodipine should be used only when the potential benefits outweigh the potential risks to the fetus.
○ Olmesartan medoxomil
Administration of drugs that directly act on the renin-angiotensin system to a pregnant woman may cause damage or death to the fetus or newborn, and dozens of such cases have been reported worldwide in patients taking angiotensin converting enzyme (ACE) inhibitors. Therefore, if you find out that you are pregnant, you should stop taking this medicine as soon as possible. Taking drugs that act directly on the renin-angiotensin system during the second or third trimester of pregnancy may cause fetal and neonatal damage, including hypotension, neonatal skull development, anuria, reversible or irreversible renal failure, and death. In addition, oligohydramnios, which is known to occur due to decreased renal function in the fetus, has been reported. Oligohydramnios is associated with limb spasms, craniofacial deformities, and lung hypoplasia. In addition, although the relationship with the drug is not clear, premature birth, intrauterine growth retardation, and open ductus arteriosus have also been reported. These adverse reactions are unlikely to be caused by in utero drug exposure, which is limited to the first trimester of pregnancy. If the embryo or fetus is exposed to angiotensin II receptor antagonists only during the first trimester, the pregnant woman must be informed of the above information. However, if the patient becomes pregnant, she should stop taking this medication as soon as possible. In rare cases, there is no drug of choice other than an angiotensin II receptor antagonist (generally occurs in less than one in 1,000 pregnant women). At this time, the pregnant woman must be informed of the potential risk to the fetus, and the amniotic fluid environment must be evaluated through continuous ultrasound examination. If oligohydramnios appears, taking this medicine should be discontinued except in cases where it is necessary to save the life of the pregnant woman. Depending on the gestational age, tests such as Contraction Stress Testing, Nonstress Testing, or Biophysical Profiling can be performed appropriately. However, oligohydramnios may not appear even after an irreversible disorder has already occurred in the fetus. Infants who have been exposed to angiotensin II receptor antagonists in utero should be closely observed for hypotension, decreased urine output, and hyperkalemia. If there is a decrease in urine volume, attention should be paid to maintaining blood pressure and renal perfusion fluid. Exchange transfusion or dialysis may be performed to restore low blood pressure and replace decreased renal function. There is no clinical experience administering olmesartan medoxomil to pregnant women. No teratogenic effects were observed when the drug was administered orally to pregnant rats at doses up to 1000 mg/kg/day (240 times the maximum recommended human dose (MRHD) on a milligram per square meter basis) and when administered to pregnant rabbits up to 1 mg/kg/day (half the maximum recommended human dose; higher doses are lethal in rabbits, so the effects on fetal development could not be assessed). However, in rats, when administered at a dose of 1.6 mg/kg/day or more, the birth weight and weight gain of the pups were significantly reduced, the time to reach developmental milestones was delayed (delays in auricular differentiation, eruption of lower incisors, abdominal hair growth, testicular descent, eyelid differentiation, etc.), and when administered at a dose of 8 mg/kg/day or more, the occurrence of renal pelvic relaxation increased in a dose-dependent manner. The dose at which no effect on developmental toxicity is observed in rats is 0.3 mg/kg/day, which is approximately 1/10 of the maximum recommended human dose of 40 mg/day.
○ Hydrochlorothiazide
Thiazide diuretics can cause hyperbilirubinemia and thrombocytopenia in newborns or infants. In addition, because the diuretic effect may result in decreased plasma volume, blood concentration, and uterine and placental blood flow, it is administered only when the therapeutic benefits are judged to outweigh the risks in late pregnancy.
8. Administration to nursing mothers
1) Amlodipine/Olmesartan Medoxomil/Hydrochlorothiazide
There is no information on the use of this medication during breastfeeding, so its use is not recommended.
2) Information on individual ingredients is as follows.
○ Amlodipine
Limited data in lactating mothers suggest that amlodipine passes into human breast milk. Because there is a possibility that adverse reactions may occur in infants, nursing mothers should stop breastfeeding or administer this drug, considering the importance of this drug. Drugs from the dihydropyridine class, which are similar calcium channel blockers, are excreted in breast milk.
○ Olmesartan medoxomil
In the case of olmesartan medoxomil, it is not known whether it passes into breast milk in humans, but in rats, it passes into low concentrations. Because there is a possibility that adverse reactions may occur in infants, breastfeeding mothers should stop breastfeeding or administer this drug, taking into account the importance of this drug.
○ Hydrochlorothiazide
Thiazide diuretics have been reported to inhibit breast milk production and transfer into breast milk. Since there is a possibility of adverse reactions in infants, avoid administering this drug while breastfeeding and discontinue breast-feeding if unavoidable.
9. Administration to children
Safety and efficacy have not been established for pediatric patients under the age of 18, so administration of this drug is not recommended.
10. Administration to elderly people
In clinical trials of this drug, no differences in safety and efficacy were observed between elderly patients aged 65 years or older and younger patients. However, it cannot be ruled out that a more sensitive reaction may occur in some elderly people.
When amlodipine was administered orally, the time to peak plasma concentration was similar in young and elderly patients. There was a tendency for amlodipine clearance to decrease in elderly patients, resulting in increased AUC and elimination half-life. The increase in AUC and elimination half-life in patients with congestive heart failure was expected given the age group of patients in this study.
In patients with hypertension, the AUC of olmesartan at steady state increased by approximately 35% in elderly patients (65 to 75 years old) compared to young patients, and increased by approximately 44% in patients aged 75 or older. This may be partly related to the average decrease in renal function in this patient group. In general, dose selection for the elderly should be cautious, usually starting at the lowest dose of the dosage range, and taking into account the frequent decline in liver, kidney, and heart function in the elderly, as well as concomitant diseases or concomitant medications.
Limited data suggest that systemic clearance of hydrochlorothiazide is reduced in elderly patients compared to younger patients.
11. Treatment in case of overdose
1) Symptoms: The maximum dose of this drug is 40mg/10mg/25mg once a day, and there are no research reports on overdose of this drug in humans. The most likely symptom of overdose of this drug is hypotension. The most frequent symptoms of olmesartan medoxomil overdose are low blood pressure and palpitations. When parasympathetic stimulation occurs, bradycardia may occur. Overdosage may cause excessive peripheral vasodilation with marked hypotension, which may result in tachycardia. In case of overdose of this drug, it is necessary to frequently monitor cardiac and respiratory function and frequently measure blood pressure. If hypotension occurs, cardiovascular support therapy, including raising blood pressure, and fluid administration should be administered. If hypotension does not respond to these therapies, attention should be paid to circulating fluid volume and urine output, and administration of vasopressors such as phenylephrine should be considered. Intravenous calcium gluconate may help reverse calcium channel blockage. Since amlodipine is highly bound to proteins, hemodialysis may not be helpful. The most common symptoms and signs that may appear in humans during hydrochlorothiazide overdose are electrolyte deficiency (hypokalemia, hypochloremia, hyponatremia) and dehydration caused by excessive diuresis. The most common signs and symptoms of overdose are nausea and lethargy. If digitalis is also administered, hypokalemia may worsen cardiac arrhythmias. Additionally, non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
2) Treatment: In case of overdose of this drug, observe the patient closely and take appropriate measures if symptoms appear. Inducing vomiting or gastric lavage may be one method, and using activated charcoal may also be useful. Serum electrolytes and creatinine should be monitored frequently, and if hypotension occurs, the patient should be placed supine and salt and fluid substitutes should be quickly administered. Clinically significant hypotension resulting from overdose of this drug requires active cardiovascular support therapy, including close monitoring of cardiac and pulmonary function and ensuring circulating fluid volume and urine output by maintaining extremities elevated above the body. Unless the use of vasoconstrictors is contraindicated, vasoconstrictors can help restore vascular tone and blood pressure. Intravenous administration of calcium gluconate may be beneficial in reversing the effects of calcium channel blockers. Since amlodipine is highly bound to proteins, hemodialysis may not be helpful. It is not known whether olmesartan or hydrochlorothiazide are removed by hemodialysis.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Avoid humidity and heat, and store carefully to avoid direct exposure to light.
3) Be careful as changing it to another container may cause an accident or is undesirable in terms of maintaining quality.
13. Pharmaceutical equivalence test information
A. The test drug amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 10/40/12.5 mg (JW Pharmaceutical Co., Ltd.) and the reference drug Sevica HCT tablet 10/40/12.5 mg (Daiichi Sankyo Korea Co., Ltd.) were administered as a single tablet to 35 healthy adults in a 2×2 crossover study on an empty stomach. As a result of measuring amlodipine, olmesartan, and hydrochlorothiazide in the blood through oral administration, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
Table: Documentation Reference
B. According to Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 5/40/12.5 mg (JW Joongwae Pharmaceutical Co., Ltd.) is the reference drug. Comparative dissolution test data with amlodipine besylate/olmesartan medoxomil/hydrochlorothiazide tablet 10/40/12.5 mg (JW Joongwae Pharmaceutical Co., Ltd.) were submitted, and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
※ This drug was manufactured using the same raw materials as Amlodipine Besylate/Olmesartan Medoxomil/Hydrochlorothiazide Tablets 10/40/12.5 mg and 5/40/12.5 mg, and the entire process was manufactured by JW Jung-Woe Pharmaceutical Co., Ltd. using the same manufacturing method.
14. Others
1) This drug and other angiotensin antagonists showed slightly less blood pressure lowering effect in black people than in other races. This is believed to be because, among black hypertensive patients, the frequency of patients with low renin levels is generally higher.
2) For patients who need rest at night, it is advisable to administer it in the morning to avoid urination at night.
5. How to save
Airtight container, stored at room temperature (1-30℃)
6. Packaging unit
30 tablets (10 tablets/Alu-Alu × 3)
7. Period of use
36 months from date of manufacture
Product Updates
Total 9items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 9 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2026.02.19 | PDF0253_201805342_Precautions for use_Olodipine HCT tablet 10_40_12.5 mg.pdf |
| 8 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2026.02.12 | PDF0397_201805342_Precautions for use_Olodipine HCT tablet 10/40/12.5mg.pdf |
| 7 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2026.02.12 | PDF0218_201805342_Precautions for use_Olodipine HCT tablet 10/40/12.5mg.pdf |
| 6 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2024.08.30 | Olodipine HCT Tablet 10│40│12.5mg_Precautions for use, change plan and change comparison table.pdfFile under review |
| 5 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2023.02.07 | Olodipine HCT Tablet_Change Proposal + Change Comparison Table.pdfFile under review |
| 4 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2022.11.16 | Olodipine HCT tablet change plan + change comparison table.pdfFile under review |
| 3 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2022.03.16 | Change plan + change comparison table_Olodipine HCT.pdfFile under review |
| 2 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2019.06.20 | PDF0001_201805342_Precautions for use (Olodipine HCT tablets 10_40_12.5mg).pdf |
| 1 | OlodipineHCT tab.10/40/12.5mg | Precautions for use | 2019.01.25 | PDF0537_201805342_Precautions for use (Olodipine HCT tablets 10_40_12.5 mg).pdf |